BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9025773)

  • 1. A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer.
    Mori K; Ohnishi T; Yokoyama K; Tominaga K
    Cancer Chemother Pharmacol; 1997; 39(4):327-32. PubMed ID: 9025773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
    Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
    Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
    Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer.
    Mori K; Hirose T; Machida S; Yokoyama K; Tominaga K
    Eur J Cancer; 1997 Mar; 33(3):503-5. PubMed ID: 9155540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Kusunoki Y; Matsui K; Nakagawa K; Hirashima T; Tamanoi M; Nitta T; Yana T
    J Clin Oncol; 1994 Jan; 12(1):90-6. PubMed ID: 7505810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer.
    Kobayashi K; Shinbara A; Kamimura M; Takeda Y; Kudo K; Kabe J; Hibino S; Hino M; Shibuya M; Kudoh S
    Cancer Chemother Pharmacol; 1998; 42(1):53-8. PubMed ID: 9619758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
    Mori K; Machida S; Yoshida T; Yoshida M; Kano Y; Tominaga K
    Cancer Chemother Pharmacol; 1999; 43(6):467-70. PubMed ID: 10321506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.
    Masuda N; Fukuoka M; Takada M; Kusunoki Y; Negoro S; Matsui K; Kudoh S; Takifuji N; Nakagawa K; Kishimoto S
    J Clin Oncol; 1992 Nov; 10(11):1775-80. PubMed ID: 1328551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
    Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
    Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
    Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
    Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical studies of irinotecan alone and in combination with cisplatin.
    Fukuoka M; Masuda N
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S105-11. PubMed ID: 8070018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer.
    Nogami N; Harita S; Ueoka H; Yonei T; Kiura K; Kamei H; Tabata M; Segawa Y; Gemba K; Tanimoto M
    Lung Cancer; 2004 Jul; 45(1):85-91. PubMed ID: 15196738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
    Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
    Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phase I study of cisplatin, ifosfamide and CPT11 with granulocyte colony-stimulating factor support in advanced non-small cell lung cancer].
    Fujita A; Takabatake H; Tagaki S; Sekine K
    Gan To Kagaku Ryoho; 1996 Sep; 23(10):1285-90. PubMed ID: 8831740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.
    Shirao K; Shimada Y; Kondo H; Saito D; Yamao T; Ono H; Yokoyama T; Fukuda H; Oka M; Watanabe Y; Ohtsu A; Boku N; Fujii T; Oda Y; Muro K; Yoshida S
    J Clin Oncol; 1997 Mar; 15(3):921-7. PubMed ID: 9060529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly administration of irinotecan (CPT-11) plus cisplatin for non-small cell lung cancer.
    Hino M; Kobayashi K; Yoshimura A; Takeda Y; Hisakatsu S; Yoneda S; Gemma A; Moriya H; Kudoh S;
    Anticancer Res; 2006; 26(6C):4697-703. PubMed ID: 17214329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
    DeVore RF; Johnson DH; Crawford J; Garst J; Dimery IW; Eckardt J; Eckhardt SG; Elfring GL; Schaaf LJ; Hanover CK; Miller LL
    J Clin Oncol; 1999 Sep; 17(9):2710-20. PubMed ID: 10561345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.